左旋咪唑上市后安全性再评价Ⅱ：严重不良反应文献分析  

Re-evaluation of Post-marketing Safety of Levamisole(2):Literature Review of its Severe Adverse Reaction

作　　者：杨学志[1] 郑荣远[1] 殷为勇[1] 朱振国[1] 朱英标[1] 曹立亚[2] 吴晔[2] 任经天[2] 

机构地区：[1]温州医学院附属第一医院神经内科浙江省神经药物流行病学研究中心,浙江温州325000 [2]国家食品药品监督管理局药品评价中心

出　　处：《药物流行病学杂志》2007年第5期280-283,共4页Chinese Journal of Pharmacoepidemiology

基　　金：国家食品药品监督管理局药品评价中心委托与资助

摘　　要：目的:了解左旋咪唑不良反应的发生情况,为临床合理用药提供参考。方法:检索1984～2005年间国内外公开发表的有关左旋咪唑上市后研究文献,进行调查登记、数据整理、统计分析。结果:共获得文献98篇,其中国内72篇,国外26篇。共报道严重不良反应638例,其中国内602例,国外36例,包括脱髓鞘脑病586例,粒细胞缺乏症6例,皮疹4例,其他不良反应42例。结论:广大用药人群和临床医生务必高度重视LMS所引起严重的不良反应,提高警惕。Objective： To provide some reasonable reference for clinical medication by investigating the adverse reaction of levamisole. Method： The literatures published between 1984 and 2005 were reviewed by re-evaluating the postmarketing levamisole and its use and then analyzed. Result： A total of 98 literatures were got, including 76 domestic literatures and 26 overseas literatures. 638 cases with adverse drug reaction （ADR） were reported, 602 cases of which were domestic and 36 cases were overseas. Among all the 638 cases with ADR, 586 cases were ill with demyelination disease, 6 cases, agranulocytosis, 4 cases, erythra and 42 cases presented some other adverse reactions. Conclusion： The most medication crowd and clinicians must pay high attention to the severe adverse reaction of levamisole and raise vigilance when using levamisole.

关 键 词：左旋咪唑 药物不良反应 文献分析 

分 类 号：R978.63[医药卫生—药品]